

# High Prevalence of HIV Persistence in CSF of Adolescents and Young Adults with Perinatally-Acquired HIV and Cognitive Impairment in the IMPAACT 2015 Study

Thor Wagner<sup>1</sup>, Camlin Tierney<sup>2</sup>, Sharon Huang<sup>2</sup>, Sharon Nichols<sup>3</sup>, Kathleen Malee<sup>4</sup>, Nicole A. Montañez<sup>5</sup>, Anne Coletti<sup>5</sup>, Hans ML Spiegel<sup>6</sup>, Megan Wilkins<sup>7</sup>, Lisa Abuogi<sup>8</sup>, Murli Purswani<sup>9</sup>, Allison Bearden<sup>10</sup>, Andrew Wiznia<sup>11</sup>, Allison Agwu<sup>12</sup>, Ellen G. Chadwick<sup>4</sup>, Douglas Richman<sup>13</sup>, Monica Gandhi<sup>14</sup>, Patrick Mehta<sup>15</sup>, Bernard Macatangay<sup>15</sup>, Stephen Spector<sup>19</sup>, Serena Spudich<sup>16</sup>, Deborah Persaud<sup>17</sup>, and Ann Chahroudi<sup>18</sup> for the IMPAACT 2015 Protocol Team

Seattle Children's Research Institute CRS<sup>1</sup>, Statistical and Data Analysis Center<sup>2</sup>, University of California San Diego<sup>3</sup>, Ann & Robert H. Lurie Children's Hospital of Chicago<sup>4</sup>, FHI 360<sup>5</sup>, Kelly <sup>6</sup>Government Solutions, Contractor to NIAID/NIH/HHS<sup>6</sup>, St. Jude Children's Research Hospital<sup>7</sup>, University of Colorado Denver<sup>8</sup>, BronxCare Health System<sup>9</sup>, University of Southern California, Los Angeles<sup>10</sup>, Jacobi Medical Center Bronx<sup>11</sup>, Johns Hopkins University Baltimore<sup>12</sup>, University of California San Diego<sup>13</sup>, University of California San Francisco<sup>14</sup>, University of Pittsburgh School of Medicine<sup>15</sup>, Yale University<sup>16</sup>, Johns Hopkins University<sup>17</sup>, Emory University School of Medicine<sup>18</sup>

## BACKGROUND

The central nervous system is a potential reservoir for HIV in adolescents and young adults (AYA) with perinatal HIV (PHIV). HIV persistence in the central nervous system may impact long-term cognitive outcomes in AYAPHIV.

IMPAACT 2015 examined AYAPHIV with cognitive impairment and receiving effective antiretroviral therapy (ART) to quantify HIV persistence in blood and cerebrospinal fluid (CSF).

# HIV DNA was DETECTED in CSF cells from a

MAJORITY of adolescents and young adults with PERINATAL HIV INFECTION and cognitive impairment on effective antiretroviral therapy

## **METHODS**

- <u>Study Description</u>: IMPAACT 2015 was an IRB-approved U.S.-based cross-sectional, multi-site, exploratory, observational study.
- <u>Study Population</u>: AYAPHIV (13-30 years old) on suppressive ART and with cognitive impairment measured at screening. Cognitive impairment was defined as NIH Toolbox Fluid Cognition Composite standard score >1 S.D. below the normative group mean (<85).
- <u>Study Procedures</u>: Participants underwent lumbar puncture (LP) to collect at least 8 ml of CSF, as well as phlebotomy and hair collection.
- Study Measurements:
  - NIH Toolbox was used to assess cognitive function.
  - HIV RNA and HIVgag/pol DNA in blood and CSF were assayed by droplet digital PCR.
  - 11 biomarkers of inflammation and neuronal injury in blood and CSF were quantified by ELISA.
  - Hair was used to quantify ART exposure levels.

#### **TABLE.** Study Participant Characteristics

Characteristic (N = 18)	Median (Q1, Q3)	Min, Max
Age, years	20 (18, 23)	13, 27
Sex		
n (%) female sex at birth	9 (50%)	na
Race		
n (%) Black or African American	14 (78%)	na
Duration of ART, years	18.3 (16.8, 20.4)	8, 25.5
Fluid Cognition Composite Score	68 (59.0, 75.0)	53.0, 80.0
Pre-entry CD4+ T cell count, cells/uL	701 (430, 1012)	143, 1342
CSF leukocytes, cells/uL	1 (0, 2)	0, 5
CSF/Plasma Albumin Ratio*	0.003 (0.002, 0.004)	0.000, 0.035

Exact binomial confidence intervals were calculated, and 41 comparisons evaluated with exact Wilcoxon rank sum tests.

\* Data on one participant not available

# RESULTS

### FIGURE 1. Prevalence of HIV RNA and **DNA in blood and CSF**

## FIGURE 2. Detectable HIV DNA in CSF is associated with higher HIV DNA levels in PBMCs

#### FIGURE 3. Neurocognitive scores trend lower in participants with detectable HIV **DNA in CSF**



## CONCLUSIONS

#### Among cognitively impaired AYAPHIV on suppressive ART with a median age of 20 years:

- LP is feasible and safe as part of a research protocol
- Quantifiable CSF HIV RNA is infrequent (1/18 participants, 5.6%)
- Detectable CSF HIV DNA is common (13/18 participants, 72%)
- Detectable HIV DNA in CSF is associated with higher HIV DNA levels in PBMCs
- Detectable CSF HIV DNA may be associated with poorer neurocognitive outcomes
- There was no association between detectable HIV in the CSF and plasma/CSF biomarkers of inflammation and neuronal injury or hair antiretroviral drug levels

#### **Pronounced CSF reservoir in AYAPHIV warrants further study**

#### LIMITATIONS

#### • Small sample size

• Cell numbers interrogated in CSF varied from 94-1950, limiting the sensitivity to detect HIV DNA

# ACKNOWLEDGMENTS

We are grateful to the study participants, IMPAACT 2015 protocol team, Community Advisory Board members, and IMPAACT 2015 participating sites (5013) Jacobi Medical Center, 5092 Johns Hopkins, 5030 Emory, 5017 Seattle Children's, 5048 Southern LA, 5114 Bronx Lebanon Hospital, 4001 Lurie Children's Hospital, 6501 St. Jude, 5112 UCLA, 4601 UCSD).

#### For more information, visit **impaactnetwork.org** and follow us:

Facebook: IMPAACTNetwork | Twitter: @IMPAACTNetwork | LinkedIn: IMPAACTNetwork

Overall support for the International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT) was provided by the National Institute of Allergy and Infectious Diseases (NIAID) with co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Mental Health (NIMH), all components of the National Institutes of Health (NIH), under Award Numbers UM1AI068632-15 (IMPAACT LOC), UM1AI068616-15 (IMPAACT SDMC) and UM1AI106716-09 (IMPAACT LC), and by NICHD contract number HHSN2752018000011. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH

Presented at AIDS 2022 – the 24th International AIDS Society Conference 29 July – 2 August 2022 Poster Number: **PESUA19**